However, 225Ac-PSMA-617 both as a single agent and in combination with 177Lu-PSMA-617 was associated with significant tumor growth retardation (P = 0.009 for tandem vs. 177Lu; P = 0.0084 for 225Ac vs. 177Lu; P > 0.999 for tandem vs. 225Ac measured 5 wk after treatment). The gene discussed is FOLH1; the disease is neoplasm.